ADAGENE INC-ADR (ADAG) Stock News

USA - NASDAQ:ADAG - US0053291078 - ADR

1.405 USD

-0.21 (-12.73%)

Last: 11/7/2025, 8:00:00 PM

1.44 USD

+0.03 (+2.49%)

After Hours: 11/7/2025, 8:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADAG Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Adagene Inc.

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

10 days ago - By: Adagene Inc.

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer

a month ago - By: Zacks Investment Research

All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy

2 months ago - By: Adagene Inc.

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

4 months ago - By: Stocktwits - Mentions: MRK

News Image

Adagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns Optimistic

2 months ago - By: Adagene Inc.

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate

2 months ago - By: Benzinga - Mentions: PACS PRPH ABP CYCN ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

2 months ago - By: Zacks Investment Research - Mentions: ANIP

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

2 months ago - By: Adagene Inc.

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

2 months ago - By: Adagene Inc.

Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China

2 months ago - By: Adagene Inc.

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

2 months ago - By: Adagene Inc.

Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor

3 months ago - By: Adagene Inc.

Adagene to Participate in Two Investor Conferences in September

3 months ago - By: Adagene Inc.

Adagene to Participate in Two Investor Conferences in September

3 months ago - By: Zacks Investment Research - Mentions: CRMD

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

3 months ago - By: Benzinga - Mentions: TRIB ONMD JAGX SNOA ...

12 Health Care Stocks Moving In Thursday's Intraday Session

3 months ago - By: Adagene Inc.

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

3 months ago - By: Adagene Inc.

Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates

4 months ago - By: Adagene Inc.

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

4 months ago - By: Adagene Inc.

Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

4 months ago - By: Adagene Inc.

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

4 months ago - By: Adagene Inc.

Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

4 months ago - By: Adagene Inc.

Adagene announces up to $25 million strategic investment from Sanofi

4 months ago - By: Adagene Inc.

Adagene announces up to $25 million strategic investment from Sanofi

5 months ago - By: Yahoo Finance - Mentions: CERO KYMR QDEL MCK ...

Cero announces two granted U.S. patents, European patent application allowance

6 months ago - By: Adagene Inc.

Adagene to Present at Jefferies Global Healthcare Conference 2025

6 months ago - By: Adagene Inc.

Adagene to Present at Jefferies Global Healthcare Conference 2025

6 months ago - By: Adagene Inc.

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

6 months ago - By: Adagene Inc.

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

7 months ago - By: Adagene Inc.

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

7 months ago - By: Adagene Inc.

Adagene Appoints John Maraganore, Ph.D. as Executive Advisor

7 months ago - By: Adagene Inc.

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

7 months ago - By: Adagene Inc.

Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting

7 months ago - By: Adagene Inc.

Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum

8 months ago - By: Adagene Inc.

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: Adagene Inc.

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update

8 months ago - By: Adagene Inc.

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

8 months ago - By: Adagene Inc.

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit

8 months ago - By: Adagene Inc.

Adagene to Present at Leerink’s Global Healthcare Conference 2025